Is FDA's Fast Subcutaneous Lunsumio VELO Approval Reshaping the Investment Case For Roche (SWX:ROG)? [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, cutting administration time from hours to about one minute. This approval underscores Roche's push toward more patient-centric oncology treatments that ease clinic resource constraints while expanding options in later-line blood cancer care. We'll now examine how this faster, subcutaneous Lunsumio VELO offering may influence Roche's investment narrative built around high-value biologics and innovation. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Roche, I think you need to believe in its ability to keep refreshing a high-value oncology and diagnostics portfolio while managing pricing and patent pressures. The Lunsumio VELO approval strengthens the near term oncology innovation story, but does not materially change the biggest current risk, which remains pricing and policy pressure
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA approves Roche's Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular LymphomaBusiness Wire
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance]Yahoo! Finance
- Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships? [Yahoo! Finance]Yahoo! Finance
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance Canada]Yahoo! Finance Canada